Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053168 | 0.97 | MTNR1A (0.47) | MTNR1AMTNR1BHTR2AHTR2CHDAC3 | |
| SCHEMBL3057715 | 0.97 | MTNR1A (0.47) | MTNR1AMTNR1BHTR2AHTR2CHDAC3 | |
| SCHEMBL3058774 | 0.89 | MTNR1A (0.49) | MTNR1AMTNR1BHDAC3NCOR2ALDH1A1 | |
| SCHEMBL8078336 | 0.88 | MTNR1A (0.43) | MTNR1AMTNR1BHTR2AHTR2CALDH1A1 | |
| SCHEMBL3060093 | 0.88 | MTNR1A (0.48) | MTNR1AMTNR1BHDAC3NCOR2ALDH1A1 | |
| SCHEMBL3061249 | 0.84 | MTNR1A (0.55) | MTNR1AMTNR1BHTR2AHTR2CALDH1A1 | |
| SCHEMBL3055224 | 0.84 | MTNR1A (0.40) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL8080132 | 0.82 | MTNR1A (0.54) | MTNR1AMTNR1BHTR2AHTR2CHDAC3 | |
| SCHEMBL8069899 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BHTR2AHTR2CHDAC3 | |
| SCHEMBL3052273 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BHTR2AHTR2CHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009026446-A9 | HDAC INHIBITORS | ARQULE, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009026446-A2 | HDAC INHIBITORS | ARQULE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | MTNR1A 2791/4885MTNR1B 3211/4885HTR2A 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.